Fusion protein · Immune activation · developed by Xilio Development
XTX301 is an engineered IL-12 cytokine conjugated to a masking domain and a half-life extension domain, joined by a tumor protease-cleavable linker. The masking domain keeps IL-12 inactive in circulation; MMP cleavage in the tumor microenvironment releases active IL-12 to activate CD8+ and CD4+ T-cells and natural killer cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05684965 | Phase 1/2 | Advanced Solid Tumor | Recruiting | XLO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XLO catalysts and pipeline →